Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. (NAUT)

Market Closed
5 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
2. 03
-0.04
-1.93%
Pre Market
$
2. 03
0 0%
286.71M Market Cap
- P/E Ratio
0% Div Yield
254,902 Volume
-0.74 Eps
$ 2.07
Previous Close
Day Range
1.92 2.1
Year Range
0.62 2.54
Want to track NAUT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 73 days

Summary

NAUT closed Friday lower at $2.03, a decrease of 1.93% from Thursday's close, completing a monthly decrease of -9.38% or $0.21. Over the past 12 months, NAUT stock gained 17.34%.
NAUT is not paying dividends to its shareholders.
The last earnings report, released on Oct 28, 2025, exceeded the consensus estimates by 0.04%. On average, the company has surpassed earnings expectations by 0.06%, based on the last three reports. The next scheduled earnings report is due on Feb 19, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

NAUT Chart

Similar

Enanta Pharmaceuticals Inc.
$ 14.6
+3.62%
Kyverna Therapeutics, Inc.
$ 7.8
-0.51%
DH
Definitive Healthcare Corp
$ 2.48
-3.13%
Spok Holdings Inc.
$ 13.02
-0.08%
CVRx, Inc.
$ 9.05
-3.21%
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Kentaro Suzuki - Chief Marketing Officer Anna Mowry - CFO & Treasurer Conference Call Participants Ji-Yon Yi William Ruby - TD Cowen, Research Division Presentation Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Third Quarter 2025 Earnings Conference Call.

Seekingalpha | 1 month ago
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2025 Earnings Call July 31, 2025 8:30 AM ET Company Participants Anna Mowry - CFO & Treasurer Parag Mallick - Co-Founder, Chief Scientist & Director Sujal M. Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Daniel Gregory Brennan - TD Cowen, Research Division Subhalaxmi T.

Seekingalpha | 4 months ago
Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Elizabeth Kolsky - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilus First Quarter 2025 earnings conference call.

Seekingalpha | 7 months ago

Nautilus Biotechnology, Inc. (NAUT) FAQ

What is the stock price today?

The current price is $2.03.

On which exchange is it traded?

Nautilus Biotechnology, Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is NAUT.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 286.71M.

When is the next earnings date?

The next earnings report will release on Feb 19, 2026.

Has Nautilus Biotechnology, Inc. ever had a stock split?

No, there has never been a stock split.

Nautilus Biotechnology, Inc. Profile

Biotechnology Industry
Healthcare Sector
Sujal M. Patel CEO
NASDAQ (NGS) Exchange
63909J108 CUSIP
US Country
134 Employees
- Last Dividend
- Last Split
10 Jun 2021 IPO Date

Overview

Nautilus Biotechnology, Inc. is a groundbreaking life sciences company in its development stage, focusing on revolutionizing the proteomics field. Founded in 2016 and based in Seattle, Washington, the company aims to significantly advance the understanding and quantification of the proteome through its innovative platform technology. The proteome, a complex array of proteins present in any biological sample, holds critical information for understanding human health and disease. By developing technologies to deeply analyze this complexity, Nautilus Biotechnology seeks to unlock new insights in biology, diagnostics, and therapeutic development.

Products and Services

  • Nautilus Platform

    An all-encompassing proteomics platform designed by Nautilus Biotechnology, this revolutionary system promises to bring unprecedented depth and precision to proteome analysis. It is an end-to-end solution featuring a combination of instruments, consumables, and sophisticated software for data analysis. The platform aims to facilitate a comprehensive understanding of the proteome's complexity, driving forward biological research and potential clinical applications.

  • Proteome Analysis System

    This high-resolution optical imaging system stands at the core of the Nautilus Platform, integrating advanced fluidics and liquid handling subsystems. Its design is tailored for seamless operation, enabling detailed and efficient analysis of protein samples. The system's capability to provide in-depth proteome insights through its state-of-the-art imaging technology positions it as a critical tool for researchers and clinicians alike.

  • Sample Preparation and Multi-Affinity Probe Reagents

    To complement its proteome analysis system, Nautilus offers a range of products designed for optimal sample preparation. This includes flow cells for sample input and multi-affinity probe reagents specially formulated for the capture and analysis of a wide array of proteins. These components are crucial for enhancing the system's sensitivity and specificity, thereby maximizing the quality and reliability of the proteomic data generated.

  • Instrument Buffers and Multi-Cycle Analysis Run System

    Supporting the operational needs of its platforms, Nautilus provides specifically designed instrument buffers and a system that allows for multi-cycle analysis runs. These solutions are engineered to ensure the platforms' smooth and effective performance during extended proteomics experiments. By facilitating multi-cycle runs, Nautilus Biotechnology enables more exhaustive and comprehensive proteome analyses, advancing the depth of biological insights that can be obtained.

Contact Information

Address: 2701 Eastlake Avenue East
Phone: 206 333 2001